ITI-1000 is under clinical development by Immunomic Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ITI-1000’s likelihood of approval (LoA) and phase transition for Recurrent Malignant Glioma took place on 19 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 19 Jul 2022 increased ITI-1000’s Phase Transition Success Rate (PTSR) for Recurrent Medulloblastoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ITI-1000 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ITI-1000 overview

ITI-1000 is under development for the treatment of glioblastoma multiforme (GBM), recurrent malignant glioma or recurrent medulloblastoma. It is administered intradermally. The vaccine candidate is a cytomegalovirus pp65-LAMP mRNA-loaded dendritic cell (DCs) vaccine. The vaccine candidate is based on Lysosomal-Associated Membrane Protein (LAMP-vax) technology.

Immunomic Therapeutics overview

Immunomic Therapeutics (ITI) is a clinical-stage biotechnology company that develops patented lysosomal-associated membrane protein or lamp technology based nucleic acid immunotherapy platforms. The company’s vaccines utilize the body’s natural biochemistry to develop immune response including antibody production, cytokine release and crITIcal immunological memory. Its oncology pipeline products at various stages of development include ITI-1000, ITI-2000, ITI-3000, ITI-4000, ITI-5000, and ITI-6000. The company’s products also include ASP-4070 and ASP-0892 for treating allergy. The company also develops LAMP-vax technology vaccines that encode the expression of a fusion protein comprising the therapeutic antigen and the LAMP targeting protein. The company partners with academic centers and biotechnology companies to study the use of the UNITE platform in treating glioblastoma and acute myeloid leukemia. ITI is headquartered in Rockville, Maryland, the US.

Quick View ITI-1000 LOA Data

Report Segments
  • Innovator
Drug Name
  • ITI-1000
Administration Pathway
  • Intradermal
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.